VERA

Vera Therapeutics, Inc.

Healthcare
Biotechnology
$2.52B market cap

Forecast run · Sep 14, 2026Upside rank 1196 of 3,136

Model Signal

ForecastQ Daily Probabilities

41.3%

49.8%

22.7%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$35.05

Price target$86.75

Implied move+147.5%

Analysts14

ForecastQ Portfolios

VERA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.